During the past decade, Rex Hematology Oncology Associates-Cary conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 8 clinical trials were completed, i.e. on average, 80% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 4 clinical trials were completed. i.e. 80% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Rex Hematology Oncology Associates-Cary" #1 sponsor was "SWOG Cancer Research Network" with 4 trials, followed by "Alliance for Clinical Trials in Oncology" with 3 trials sponsored, "US Oncology Research" with 3 trials sponsored, "NRG Oncology" with 2 trials sponsored and "ECOG-ACRIN Cancer Research Group" with 2 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Rex Hematology Oncology Associates-Cary" #1 collaborator was "National Cancer Institute (NCI)" with 10 trials as a collaborator, "Canadian Cancer Trials Group" with 3 trials as a collaborator, "Bayer" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator and "Celgene Corporation" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Rex Hematology Oncology Associates-Cary" are "Anatomic Stage II Breast Cancer AJCC v8" (2 trials), "Anatomic Stage IIA Breast Cancer AJCC v8" (2 trials), "Anatomic Stage IIB Breast Cancer AJCC v8" (2 trials), "Anatomic Stage IIIA Breast Cancer AJCC v8" (2 trials) and "Breast Cancer" (2 trials). Many other conditions were trialed in "Rex Hematology Oncology Associates-Cary" in a lesser frequency.

Most popular intervention types in "Rex Hematology Oncology Associates-Cary" are "Drug" (16 trials), "Other" (7 trials), "Biological" (3 trials), "Procedure" (3 trials) and "Radiation" (2 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (2 trials), "Cyclophosphamide" (2 trials), "Paclitaxel" (2 trials), "Quality-of-Life Assessment" (2 trials) and "Questionnaire Administration" (2 trials). Other intervention names were less common.

The vast majority of trials in "Rex Hematology Oncology Associates-Cary" are 14 trials for "All" genders, 3 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Rex Hematology Oncology Associates-Cary". undefined are not yet recruiting, 4 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Rex Hematology Oncology Associates-Cary, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Rex Hematology Oncology Associates-Cary, 0 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".